Prognostic implication of p53 protein expression in relation to nuclear pleomorphism and the MIB-1 counts in breast cancer

Breast Cancer

Volumn 11, Issue 2, 2004, Pages 160-168

  Tsutsui, Shinichi ^a   Yasuda, Kazuhiro ^a   Higashi, Hidefumi ^a   Tahara, Kouichirou ^a   Sugita, Satoshi ^a   Eguchi, Hidetoshi ^a   Kayashima, Hiroto ^a   Miyazaki, Nobuhiko ^a   Muto, Yoichi ^a   Era, Shoichi ^a  

^a NATIONAL HOSPITAL ORGANIZATION BEPPU MEDICAL CENTER   (Japan)

Author keywords

Breast cancer; MIB 1; Nuclear pleomorphism; P53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CELL NUCLEUS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16544395904     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968296     Document Type: Article

References (51)

1. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991. (Pubitemid 21896613)
2. Lane DP: P53, guardian of the genome. Nature 358:15-16, 1992.
3. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32:39-47, 1994. (Pubitemid 24322246)
4. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine A J: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539, 1988.
5. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S: Prognostic value of p53 protein expression in breast cancer; An immunohistochemical analysis of frozen sections in 514 Japanese women. Breast Cancer 8:194-201, 2001.
6. Isola J, Visakorpi T, Holli K, Kallioniemi O: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992.
7. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993. (Pubitemid 23046895)
8. Lipponen P, Ji H, Aaltomaa S, Syrjanen S, Syrjanen K: P53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55:51-56, 1993. (Pubitemid 23261705)
9. Ffiedrichs K, Gluba S, Eidtmann H, Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72:3641-3647, 1993. (Pubitemid 24000599)
10. Stenmark-Askmalm M, Stal O, Sullivan S, Ferraud L, Sun X, Carstensen J. Nordenskjold B: Cellular Accumulation of p53 protein: And independent prognostic factor in stage I] breast cancer. EurJ Cancer 30A:175. 180, 1994. (Pubitemid 24081284)
11. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre J: Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study on 942 cases. Breast Cancer Res Treat 36:71-81, 1995.
12. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall D J: Relationship between p53 gene abnormalities and other tumor characteristics in breast-cancer prognosis. IntJ Cancer 69:135-141, 1996. (Pubitemid 26164863)
13. Fresno M, Molina R, Perez del Rio MJ, Alvarez S, Diaz-Iglesias JM, Garcia I, Herrero A: P53 expression is of independent predictive value in lymph node-negative breast carcinoma. Eur J Cancer 33:1268-1274, 1997. (Pubitemid 27359647)
14. Davidoff AM, Herndon II JE, Glover NS, Kerns BM, Pence JC, Iglehart JD, Marks JR: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110:259-264, 1991.
15. Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992.
16. Swan A, Randall B, Angus B, Wright C, Henry JA, Ostrowske J, Hennessy C, Lennard TWJ, Corbett I, Home CHW: Refinolastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study. J Pathol 168:23-28, 1992.
17. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum Patho124:469-476, 1993. (Pubitemid 23145798)
18. Stenmark-Askmalm M, Stal O, Olsen K, Nordenskjold B: P53 as a prognostic factor in stage I breast cancer. Br J Cancer 72:715-719, 1995.
19. Silverstrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B, Veronesi U: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 2:2007-2013, 1996. (Pubitemid 27006633)
20. Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G: Abnormal p53 immunoreactivity and prognosis in nodenegative breast carcinomas with long-term follow-up. Virchows Archiv A Pathol Anat 421:291-295, 1992.
21. Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blarney RW, Ellis IO: P53 expression in human breast carcinoma: Relationship to expression of epidermal growth factor receptor, cerbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66:583-588, 1992.
22. Jacquemier J, Moles JP, Penault-Llorca F, Adelaide J, Torrente M, Viens P, Birnbaum D, Theillet C: P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results. Br J Cancer 69:846-852, 1994. (Pubitemid 24140662)
23. Cunningham JM, Ingle JN, Jung SH, Cha SS, Wold LE, Farr G, Witzig TE, Krook JE, Wieand HS, Kovach JS: P53 gene expression in node-positive breast cacner: Relationship to DNA ploidy and prognosis. J Natl Cancerlnst 86:1871-1873, 1994.
24. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V, Syrjanen K: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177:225-232, 1995.
25. Rosen PP, Lesser ML, Arroy CD, Cranor M, Borgen P, Norton L: P53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Onco113:821-830, 1995.
26. Haerslev T, Jacobsen GK: An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum Patho126:295-301, 1995.
27. Fitzgibbonsss PL, Page DL, Weaver D, Thor AD, Allred C, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124:966-978, 2000.
28. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957.
29. Rank F, Dombernowsky P, Jespersen NCB, Pedersen BV, Keiding N: Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial. Cancer 60:1599-1305, 1987.
30. Thor AD, Liu S, Moore II DH, Edgerton SM: Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 17:470-477, 1999. (Pubitemid 29075230)
31. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D: P53 expression in breast cancer. Int J Cancer 41:178-183, 1988. (Pubitemid 18061140)
32. Hurlimann J: Prognostic value of p53 protein expression in breast carcinomas. Path Res Pract 189:996-1003, 1993. (Pubitemid 23363272)
33. Merlo GR, Bernardi A, Diella F, Venesio T, Cappa APM, Callhan R, Liscia D̈: In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int J Cancer 54:531-535, 1993. (Pubitemid 23188179)
34. Sirvent JJ, Salvado MT, Santafe M, Martinez S, Brunet J, Alvaro T, Palacios J: P53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation faraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol 10:531-539, 1995.
35. Markis A, Allred DC, Powles TJ, Dowser M, Fernando IN, Trott PA, Ashley SE, Ormerod MG, Titley JC, Osborne CK: Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 44:65-74, 1997. (Pubitemid 27179770)
36. Leonardi E,Cristofori A, Caffo O, Palma PD: Cytometric DNA analysis and prognostic biomarkers in breast carcinoma. Expression of P53 product in the different ploidy classes. Anal Cell Pathol 15:31-45, 1997. (Pubitemid 27448891)
37. Bankfalvi A, Schmitz K, Mock T, Kemper M, Cubick C, Bocker W: Relationship between AgNOR proteins, Ki-67 antigen, p53 immunophenotype and differentiation markers in archival breast carcinomas. Anal Cell Pathol 17:231-242, 1998. (Pubitemid 29243076)
38. Prioleau J, Schnitt SJ: P53 antigen loss in stored paraffin slides. New EnglJMed 332:1521-1522, 1995.
39. Bruner JM, Connelly JH, Saya H: P53 protein immunostaining in routinely processed paraffin-embedded sections. Mod Pathol 6:189-194, 1993.
40. MacGrogan G, Jollet I, Huet S, Sierankowski G, Picot V, Bonichon F, Coindre JM: Comparison of quantitative and semiquanfitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol 10:769-776, 1997. (Pubitemid 27374846)
41. Jansen RLH, Hupperets PSGJ, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC, Hillen HFP: MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460-465, 1998. (Pubitemid 28360632)
42. Gasparini G, Boracchi P, Verderio P, Bevilacqua P: Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric s-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. IntJ Cancer 57:822-829, 1994. (Pubitemid 24216818)
43. Kesgegian AA, Cnaan A: Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1 counts. AmJ Clin Pathol 104:42-49, 1995.
44. Clahsen PC, van de Velde CJH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Broek L, va de Vijver IVJJ: The utility of mitotic index, oestrogen receptor and I45-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Onco125:356-363, 1999. (Pubitemid 29364220)
45. Pierga JY, Leroyer Aa, Viehl P, Mosseri V, Chevillard S, Magdelenat H: Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 37:57-64, 1996. (Pubitemid 26028246)
46. MolinoA, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, Nortilli R, Pelosi G, Cetto GL: Ki-67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis. Int J Cancer 74:433-437, 1997. (Pubitemid 27400164)
47. Brown RW, Allred DC, Clark GM, Osborne CK, Hilsenbeck SG: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585-592, 1996. (Pubitemid 26099178)
48. Haghbin M, McCue PA, Mansfield CM, Komarnicky LT, Benammar A, Schwartz GF: Correlation of flow cytometry to clinical factors, hormone receptors, and histopathological grade in stage I and lI invasive breast carcinoma. Am J Clin Onco119:54-58, 1996. (Pubitemid 26037674)
49. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immuno1133:1710-1715, 1984. (Pubitemid 14035254)
50. Cattoretti G, Becker MHG, Key G, Duchrow M, Schluter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwaveprocessed formalin-fixed paraffin sections. J Pathol 168:357-363, 1992. (Pubitemid 23013251)
51. Michalovitz D, Halevy O, Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680, 1990.